Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation)

American Journal of Obstetrics and Gynecology
C J CohenJ Rodin

Abstract

Between 1974 and 1982, 273 patients with epithelial cancer of the ovary (International Federation of Gynaecology and Obstetrics Stages III and IV) were randomized in four therapeutic trials. In Trial I Adriamycin plus cisplatin versus cisplatin alone versus thiotepa plus methotrexate was tested. The superiority of Adriamycin plus cisplatin in producing the best response rate led to its use as the reference arm in subsequent trials. All investigational arms included cisplatin plus other drugs (cyclophosphamide, Adriamycin, hexamethylmelamine, and thiotepa) in various combinations. Eligibility for second look required complete clinical remission and completion of at least 10 cycles of chemotherapy. To date, 73 second-look operations have been performed on randomized patients. An additional 43 nonrandomized patients underwent second-look procedures and are analyzed separately. Between 40% and 46% of patients treated with cisplatin regimens had no disease at second look. Cell differentiation and volume of postoperative disease did not influence response.

Citations

May 15, 1985·American Journal of Obstetrics and Gynecology·K C PodratzT A Gaffey
Jun 1, 1992·American Journal of Obstetrics and Gynecology·R F Unzelman
Mar 1, 1989·Baillière's Clinical Obstetrics and Gynaecology·W T Creasman, G L Eddy
Nov 1, 1992·Gynecologic Oncology·J F LeakeJ D Woodruff
Oct 1, 1989·Gynecologic Oncology·V K MalviyaG Deppe
Jan 1, 1985·Journal of Clinical Ultrasound : JCU·E W Sonnendecker, A M Butterworth
Apr 1, 1985·European Journal of Cancer & Clinical Oncology·K AaboB L Sørensen
Jul 1, 1987·British Journal of Obstetrics and Gynaecology·D J CruickshankA Klopper
Oct 1, 1986·Disease-a-month : DM·K D SabbathP Calabresi
Oct 1, 1990·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·T KamuraH Nakano
Jan 1, 1984·Journal of Cancer Research and Clinical Oncology·R M Canetta, S K Carter
Jan 27, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J RahamanC J Cohen
Nov 26, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M E GordinierR S Freedman
Nov 1, 1988·The Australian & New Zealand Journal of Obstetrics & Gynaecology·R M Rome, D W Fortune
Dec 1, 1988·British Journal of Obstetrics and Gynaecology·K BertelsenJ E Andersen
Oct 10, 2002·British Journal of Cancer·J SandercockW Qian
May 5, 2000·The Cochrane Database of Systematic Reviews·L Stewart, UNKNOWN Advanced Ovarian Cancer Trialists Group
Oct 1, 1984·Cancer·R AmornmarnM J Wizenberg
Jan 30, 2003·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·T SimsekB Trak
Apr 22, 1992·International Journal of Cancer. Journal International Du Cancer·D J CruickshankW T Fullerton
Feb 14, 1985·The New England Journal of Medicine·G S RichardsonJ H Nelson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.